



Bernard Testa, Stefanie D. Krämer


The Biochemistry of Drug Metabolism: Conjugations, Consequences of Metabolism, Influencing Factors




Allele and phenotype distributions



Africans



Caucasians



Chinese

The Biochemistry of Drug Metabolism: Conjugations, Consequences of Metabolism, Influencing Factors

Bernard Testa, Stefanie D. Krämer



Verlag Helvetica Chimica Acta · Zürich



WILEY-VCH

Prof. Dr. Bernard Testa
Pharmacy Department
University Hospital Centre
CHUV - BH 04
46 rue du Bugnon
CH-1011 Lausanne
Switzerland

PD Dr. Stefanie D. Krämer
Institute of Pharmaceutical Sciences
Department of Chemistry and Applied Biosciences
ETH Hönggerberg, HCI G494
CH-8093 Zürich
Switzerland

This book was carefully produced. Nevertheless, authors and publishers do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details, or other items may inadvertently be inaccurate.

Published jointly by
VHCA, Verlag Helvetica Chimica Acta, Zürich (Switzerland)
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim (Federal Republic of Germany)

Editorial Directors: Dr. M. Volkan Kisakürek, Thomas Kolitzus
Production Manager: Bernhard Rügemer
Cover Design: Jürg Riedweg

Cover Illustration:
Complex between human UDP-glucuronyltransferase (UGT2B7), its cofactor UDP-glucuronic acid, and morphine as substrate (see Fig. 4.41 for details; courtesy of Dr. Giulio Vistoli, University of Milan).

Library of Congress Card No. applied for

A CIP catalogue record for this book is available from the British Library

Die Deutsche Bibliothek – CIP-Cataloguing-in-Publication-Data

A catalogue record for this publication is available from Die Deutsche Bibliothek

ISBN-10 3-906390-54-3
ISBN-13 978-3-906390-54-3

© Verlag Helvetica Chimica Acta, Postfach, CH-8042 Zürich, Switzerland, 2010

Printed on acid-free paper.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printing: Konrad Tritsch, Print und Digitale Medien, D-97199 Ochsenfurt-Hohestadt
Printed in Germany

**The Biochemistry of
Drug Metabolism:
Conjugations, Consequences of
Metabolism, Influencing Factors**



We dedicate this book to all scientists who share our fascination with the endless marvels and complexity of the living world. May it continue to burgeon!

I also dedicate this work to the fond memory of Prof. *William F. Trager* (1937–2009), a quiet scholar and a dear friend. His groundbreaking contributions have opened our eyes to the catalytic intricacies of xenobiotic metabolism and their consequences.

B. T.

Foreword

When I was a lad, drug metabolism was a collection of interesting but disparate and often dissonant facts. Integration of this information and understanding of the associated issues is now an essential component of successful drug discovery and development and promises, through pharmacogenetics, metabolomics, and informatics, to have an increasingly direct impact on health care. As the 'song' has become more complex, there is a real need for great 'singers' to render it in an intelligible, inspiring yet concise manner.

Bernard Testa and *Stefanie Krämer* are a highly accomplished duo, and the second volume of their *magnus opus* takes the score forward to include conjugation reactions and enzymes, the various manifestations of the bioactivity of drug metabolites, and inter- and intra-individual variability (the effects of 'nature' and 'nurture', respectively, on drug metabolism). The piece is characterized by a continuous counterpoint between principles and well-chosen, contemporary examples, with careful attention to definitions and orchestration around basic chemistry (and stereochemistry). While the range of the content is enormous, the device of pinning text to *Powerpoint*TM slides is elegantly effective in providing clarity and conciseness. Many of us who attempt to teach drug metabolism will applaud the opportunity to reprise this material in improving our own presentations – with due acknowledgement to the original composers of course. As well as providing the basis for an understanding of the principles of drug metabolism to those new to the subject, this volume together with the first one represents an invaluable reference source for those interested in the challenge of being able to predict drug metabolism from chemical structure and, in a broader context, of modelling and simulating pharmacokinetic behavior in general.

Bravo to *Testa* and *Krämer* for their virtuoso performance!

September 2009

Geoff Tucker
Emeritus Professor, University of Sheffield,
and Chairman, *Simcyp Ltd*, Sheffield, UK

Preface

Our objectives when undertaking this Work were twofold. First and as research scientists, we aimed at offering a broad and structured portrayal of drug and xenobiotic metabolism, a science whose amazing advances in recent decades and years has contributed to a genuine change of paradigm in drug research. These advances are both factual and conceptual, with an ever deepening understanding of the mechanisms operating and regulating drug metabolism at the biomolecular, cellular, and organismic levels. Our second objective derives from our vocation as teachers, which has taught us that in education content cannot be separated from form – that presentation is meaningful in that it conveys information and contributes to the growth and transmission of knowledge.

As explained in the *Preface of Volume 1*, the layout of the present Work lies halfway between a traditional text enhanced with scattered illustrations, and a book of images with minimal text. In fact, it turns out that the elaboration of clearly designed, logically structured, and easily understandable schemes requires an even greater cognitive input than text writing – partly because such schemes are bidimensional and so are able to show explicit connections. The consistently positive reviews *Volume 1* has received have been an encouragement and our best reward. We are now pleased to submit *Volume 2* which completes and concludes our Work. Its *Part 4* (Conjugation Reactions) follows *Part 2* (Redox Reactions) and *Part 3* (Hydrolyses) in *Volume 1*, and gives a logically structured and comprehensive review on conjugation reactions and the involved enzymes. Its *Part 5* (Metabolism and Bioactivity) places drug and xenobiotic metabolism in the broader context of pharmacological and toxicological sciences providing insightful concepts and examples of bioactivation and toxification, respectively, which are fascinating to read and teach. As for *Parts 6* and *7* (Inter-Individual Factors and Intra-Individual Factors, respectively, affecting drug metabolism), their topics including genetic variability in drug metabolism and regulation mechanisms of enzyme expression and activity are presented in unusual depth and breadth.

Please learn from this Work and take pleasure in doing so – as every teacher hopes for their students.

January 2010

Bernard Testa and Stefanie D. Krämer

Contents

Part 4	Reactions of Conjugation and Their Enzymes	1
4.1.	Introduction	3
4.2.	Methylations	8
4.2.1.	<i>O</i> -Methylation	9
4.2.2.	<i>N</i> -Methylation	13
4.2.3.	<i>S</i> -Methylation	17
4.2.4.	<i>As</i> -Methylation	21
4.3.	Sulfonations and Phosphorylations	23
4.3.1.	An Introduction to Sulfotransferases	23
4.3.2.	<i>O</i> -Sulfonation of Phenols	28
4.3.3.	<i>O</i> -Sulfonation of Alcohols	31
4.3.4.	<i>O</i> -Sulfonation of <i>N</i> -Oxygenated Compounds	33
4.3.5.	<i>N</i> -Sulfonation of Amines	35
4.3.6.	<i>O</i> -Phosphorylation	36
4.4.	Glucuronidations and Other Glycosidations	37
4.4.1.	An Introduction to Glucuronosyltransferases	37
4.4.2.	<i>O</i> -Glucuronidation of Phenols	42
4.4.3.	<i>O</i> -Glucuronidation of Alcohols	46
4.4.4.	<i>O</i> -Glucuronidation of Hydroxylamines and Hydroxylamides	49
4.4.5.	Formation and Reactivity of Acyl Glucuronides	50
4.4.6.	<i>N</i> -Glucuronidation of Primary and Secondary Amides and Amines	56
4.4.7.	<i>N</i> -Glucuronidation of Tertiary Amines	59
4.4.8.	<i>N</i> -Glucuronidation of Other Aromatic Heterocycles	61
4.4.9.	<i>S</i> - and <i>C</i> -Glucuronidations	64
4.4.10.	Other Glycosylations	65
4.5.	Acetylations and Other Acylations	70
4.5.1.	An Introduction to Acetyltransferases	70
4.5.2.	<i>N</i> -Acetylation of Medicinal Amines and Amides	73
4.5.3.	<i>N</i> - and <i>O</i> -Acetylation of Xenobiotics	77
4.5.4.	Fatty Acid Conjugation of Sterols	79
4.6.	Formation and Fate of Coenzyme A Conjugates	80
4.6.1.	Introduction	80
4.6.2.	Amino Acyl Conjugates of Carboxylic Acids	83
4.6.3.	Ester Conjugates of Carboxylic Acids	86
4.6.4.	Metabolites with a Modified Acyl Moiety	91

4.7. Glutathione and Its Reactions	97
4.7.1. Enzymes and Mechanisms	97
4.7.2. Reactions of Glutathione Addition	106
4.7.3. Reactions of Glutathione Addition–Elimination.	121
4.7.4. Reductions Following Glutathione Conjugation	132
4.8. Reactions of Amines with Carbonyls	134
 Part 5 Metabolism and Bioactivity	167
5.1. Drug–Biosystem Interactions	169
5.2. Metabolism and Pharmacological Activity	172
5.2.1. Introduction	172
5.2.2. Drugs without Active Metabolite: The Case of Soft Drugs	175
5.2.3. Drugs with Active Metabolites	177
5.2.4. Prodrug Design: Objectives and Chemical Strategies	182
5.3. Metabolism and Toxicity	204
5.3.1. Mechanisms and Consequences of Toxicification.	204
5.3.2. Toxicification and Detoxification of Selected Chemicals and Drugs . .	215
5.3.3. Conclusion	236
 Part 6 Inter-Individual Factors Affecting Drug Metabolism	261
6.1. Introduction	264
6.2. Evolution of Drug-Metabolizing Enzymes	266
6.3. Species Differences in Drug Metabolism	273
6.3.1. Introduction	273
6.3.2. Examples of Species Differences in Drug Metabolism	276
6.3.3. Relevance of Species Differences in Drug Metabolism.	286
6.3.4. Xenobiotic Biotransformation by Non-Mammalian Organisms	287
6.4. Genetic Polymorphisms in Drug-Metabolizing Enzymes	292
6.4.1. Introduction	292
6.4.2. Polymorphisms of CYP Enzymes	299
6.4.3. Polymorphisms of Other Oxidoreductases.	321
6.4.4. Polymorphisms of Esterases.	329
6.4.5. Polymorphisms of Transferases	331
6.4.6. Clinical Relevance of Genetic Polymorphisms of Drug-Metabolizing Enzymes	346
6.4.7. Consequences in Drug Development	350
6.5. Sex-Related Differences in Drug Metabolism	351
6.5.1. Introduction	351
6.5.2. Sex-Related Differences in Human	352
6.5.3. Sex-Related Differences in Rats	354
6.6. Personalized Pharmacotherapy Related to Inter-Individual Differences in Drug Metabolism	356

Part 7	Intra-Individual Factors Affecting Drug Metabolism	375
7.1.	Introduction	377
7.2.	Regulation Mechanisms from Gene Transcription to Protein Activity	381
7.2.1.	General Control Mechanism in Eukaryotic Cells	381
7.2.2.	Epigenetic Transcription Control in Higher Organisms	382
7.2.3.	Transcriptional Control in Higher Organisms	386
7.2.4.	RNA Processing Control	433
7.2.5.	Translational Control	434
7.2.6.	Inhibition of Protein Degradation	435
7.2.7.	Enzyme Inhibition	436
7.2.8.	Enzyme Heteroactivation	462
7.3.	Physiological Factors	463
7.3.1.	Introduction	463
7.3.2.	Tissue-Specific Drug Metabolism	464
7.3.3.	Influence of Day Time	476
7.3.4.	Influence of Age	480
7.3.5.	Mechanisms of Sex-Related Differences	497
7.3.6.	Influence of Pregnancy	498
7.4.	Pathological Conditions	502
7.4.1.	Introduction	502
7.4.2.	Inflammation and Infection	504
7.4.3.	Diabetes	505
7.5.	Drug–Drug Interactions	506
7.5.1.	Introduction	506
7.5.2.	Different Effects of Altered Enzyme Activity on Low- and High-Extraction Drugs	508
7.5.3.	CYP Substrates with Altered Pharmacokinetics Caused by Enzyme Induction or Inhibition	510
7.5.4.	Drug–Drug Interactions Involving Enzymes Other than CYPs	512
7.5.5.	Drug Interactions with Herbal Remedies	513
7.6.	Influence of Food, Drinks, Tobacco, and Pollutants	515
7.6.1.	Influence of Food and Drinks on Drug Metabolism	515
7.6.2.	Influence of Ethanol	523
7.6.3.	Influence of Tobacco Smoke	524
7.6.4.	Influence of Pollutants	525
Index		559

Part 4

Reactions of Conjugation and Their Enzymes

This *Part 4* of our biochemical introduction to drug metabolism [1–4] presents the reactions of conjugation and their enzymes. As we shall see, reactions of conjugation are also a major focus of interest in the metabolism of drugs and other xenobiotics. Books specifically dedicated to conjugation reactions are rare [5], but much recent information can be found in book chapters (*e.g.*, [6][7]).

For a reaction of conjugation to occur, a *suitable functional group* must be present in the substrate, which will serve as the anchoring site for an endogenous molecule or moiety such as CH_3 , sulfate, glucuronic acid, or glutathione. Conjugation reactions are thus synthetic (*i.e.*, anabolic) reactions whose products are of modestly to markedly higher molecular weight than the corresponding substrate. As for the anchoring group, it can either be present in a xenobiotic or be created by a functionalization reaction. In other words, reactions of conjugation are able to produce *first-generation* as well as *later-generation metabolites*. We, therefore, consider as unfelicitous the term of ‘phase II reactions’ commonly used to designate conjugations.

A first issue when discussing reactions of conjugation will be to offer a clear definition. As we shall see, a number of criteria exist, all of which show some degree of fuzziness, and only one of which must necessarily be met. This has indeed led to some confusion with reactions of hydrolysis, which some biochemists have viewed as conjugation. We oppose such a view for reasons previously explained [3]. To repeat what we stated, reactions of hydrolysis are not catalyzed by *transferases* (EC 2) but by *hydrolases* (EC 3) [8], and water is not an endogenously synthesized molecule or moiety linked covalently to a cofactor.

Reactions of conjugation, like the reactions of functionalization we saw in *Parts 2* and *3*, act on exogenous substrates (*i.e.*, *xenobiotics* [1]) as well as endogenous substrates (*i.e.*, *endobiotics*). This dual functionality may create a potential for metabolic interaction between a drug and an endogenous substrate, a frequently overlooked mechanism of toxicity. Thus, there may be competitive affinity for the catalytic site of an endobiotic-metabolizing enzyme, or there may be competition for the limited supply of a cofactor. A typical example of the latter case is found with *paracetamol*, a high-dose drug undergoing extensive glucuronidation whose administration is forbidden to neonates and babies, since it deprives them of the glucuronic acid they need to detoxify bilirubin.

Part 4 Reactions of Conjugation and Their Enzymes

4.1. Introduction

4.2. Methylations

4.3. Sulfonations and Phosphorylations

4.4. Glucuronidations and Other Glycosidations

4.5. Acetylations and Other Acylations

4.6. Formation and Fate of Coenzyme A Conjugates

4.7. Glutathione and Its Reactions

4.8. Reactions of Amines with Carbonyls

Fig. 4.1. The structure of this *Part* follows custom as much as logic. First, an *introductory Chapter* will present an *overview* of the reactions of conjugation, their criteria, and their similarities and differences with functionalization reactions. As for the major reactions to be discussed in the subsequent *Chapters*, there is no overwhelming argument for preferring one order over another. We shall begin with the rather straightforward case of the reactions of *methylation* (*Chapt. 4.2*). Reactions of *sulfonation* (*Chapt. 4.3*) and *glucuronidation* (*Chapt. 4.4*) sometimes compete for the same substrates and will, therefore, be treated in sequence. Together with sulfonation, we will have a few things to say about reactions of *phosphorylation*, whose rarity should not obscure their significance in the activation of some drugs. *Chapt. 4.5* and *4.6* center on *coenzyme A*, but with a difference. Reactions of *acetylation* (*Chapt. 4.5*) follow the usual pattern in having the conjugating moiety carried by the coenzyme, here coenzyme A. In contrast, there is a variety of reactions where the substrate (be it a xenobiotic or an endobiotic) is coupled to coenzyme A prior to being processed along vastly different pathways (*Chapt. 4.6*). *Chapt. 4.7* presents *glutathione* and its reactions, a topic of marked biocomplexity and great toxicological significance.


A few unclassifiable reactions will be summarized in *Chapt. 4.8*.

4.1. Introduction		
Chemical entities being transferred to or from the substrates		
Functionalizations (Phase I)		Conjugations (Phase II)
Redox reactions	Hydrolyses	
O	H ₂ O	Methyl group (<i>Chapt. 4.2</i>)
O ₂	HO ⁻	Sulfuric or phosphoric acid (<i>Chapt. 4.3</i>)
e ⁻	Following conjugation with Coenzyme A (<i>Chapt. 4.6</i>)	Glucuronic acid and some sugars (<i>Chapt. 4.4</i>)
2 e ⁻		Acetyl or other acyl groups (<i>Chapt. 4.5</i>)
H ⁻ (hydride)		Glycine or other amino acids
		Diglycerides or other lipids
		Cholesterol or other sterols
		Ethyl or other short alkyl groups
		<i>β-Oxidation</i>
		Chain elongation by C ₂ units
		<i>Inversion of configuration</i>
		Glutathione (<i>Chapt. 4.7</i>)
		Carbonyl compounds, CO ₂ (<i>Chapt. 4.8</i>)

Fig. 4.2. This *Figure* is a slightly amended form of *Fig. 1.12* we saw in *Part I* [1], with a few additional details. The focus here is on the *conjugating moiety* being transferred to the substrate as a result of a conjugation reaction. Reference is made to *Chapt. 4.2–4.8* to help the readers get a better view of the present *Part*. We also have here a first glance at the different pathways which *xenobiotic–coenzyme A conjugates* can follow. Two of these pathways are not conjugations *stricto sensu* and, for this reason, are written in italics. Nevertheless, they will be discussed here, since a coenzyme A conjugate is the indispensable intermediate. These two pathways are the unidirectional inversion of configuration of profens (and a few other xenobiotics) and the *β*-oxidation of fatty acid analogs. As for the reactions in *Chapt. 4.8*, they represent poorly investigated pathways nevertheless worthy of some attention.

Criteria of reactions of xenobiotic conjugation

- 1) A xenobiotic substrate is **coupled** to an endogenous molecule (the endocon) ...
- 2) ... which is usually **polar**, ...
- 3) ... of **medium mol. wt.** ($\sim 100 - 300$ Da), ...
- 4) ... and carried by a **coenzyme**.
- 5) The reaction is catalyzed by a **transferase**.



Criterion 1 is essential. The other criteria are not.

Fig. 4.3. Conjugation reactions are characterized by a number of *criteria* which are presented here [5][6][9]. *First* and above all, they involve an endogenous molecule (called the *endogenous conjugating moiety*, and sometimes abbreviated as the 'endocon') with which the substrate is coupled. This is the *absolute criterion* of conjugation reactions, although, as we shall see, there may be arbitrariness in deciding whether a conjugating moiety such as CO_2 is endogenous. *Second*, this endogenous molecule or moiety is generally polar (*hydrophilic*) or even highly polar, but there are exceptions. *Third*, the *size* of the endocon is generally in the range of $100-300$ Da. *Fourth*, the endogenous conjugating moiety is usually carried by a *cofactor*, with the chemical bond linking the cofactor and the endocon being a high-energy one such that the *Gibbs* energy released upon its cleavage drives the transfer of the endocon to the substrate. *Fifth*, conjugation reactions are catalyzed by enzymes known as *transferases* (EC 2) which bind the substrate and the cofactor in such a manner that their close proximity allows the reaction to proceed. The metaphor of transferases being a '*nuptial bed*' has not escaped some biochemists. It is important from a biochemical and practical viewpoint to note that *Criteria 2-5* considered separately are neither sufficient nor necessary to define conjugation reactions. They are not sufficient, since, in hydrogenation reactions (*i.e.*, typical reactions of oxidoreduction), the hydride is also transferred from a cofactor (NADPH or NADH). And they are not necessary, since they all suffer from some important *exceptions* (see next *Figure*).

How are the conjugation criteria satisfied?					
Criteria Reactions	1 (endocon)	2 (polar)	3 (medium mol. wt.)	4 (co- enzyme)	5 (trans- ferase)
Methylations	+	0	0	+	+
N-Methylations of aromatic azaheterocycles	+	+	0	+	+
Sulfonations, phosphorylations	+	+	+	+	+
Glucuronidations	+	+	+	+	+
Acetylations	+	(+)	0	+	+
Amino acid conjugations	+	+	+	0	+
Conjugations with lipids or sterols	+	0	0	0	+
C ₂ Elongation	+	0	0	+	+
Glutathione conjugations	+	+	0	0	+ or 0
Conjugations with carbonyl compounds, CO ₂	+	+	+ or 0	0	0

Fig. 4.4. This *Figure* summarizes in tabular form the cases of *compliance and non-compliance* to the five conjugation criteria. As can be seen, *Criterion 1* is indeed the only one that knows no exception, since all conjugating moieties involved are indeed endogenous. Thus, the C₂ unit in chain elongation is derived from acetyl-coenzyme A (*Chapt. 4.6*). Most of the CO₂ used in the formation of carbamic acids (*Chapt. 4.8*) is clearly also produced *in vivo*. The criterion of polarity of the endocon (*Criterion 2*) knows only two major exceptions, namely the coupling of xenobiotic carboxylic acids to sterols or to diglycerides (to yield mixed triglycerides), and the C₂ chain elongation (*Chapt. 4.6*). The transfer of a CH₃ group is special, since it adds a hydrophobic moiety except when forming quaternary ammonium metabolites (*Chapt. 4.2*). The CH₃ group, being small, is also an exception to *Criterion 3* as is the acetyl moiety. But we also have relatively large endocons such as sterols (*Chapt. 4.6*) and glutathione (*Chapt. 4.7*). As for the conjugating moiety being carried by a coenzyme (*Criterion 4*), exceptions are glutathione (*Chapt. 4.7*), carbonyl compounds (*Chapt. 4.8*), and all reactions in *Chapt. 4.6*, since here and as stated it is the substrate rather than the endocon that is attached to coenzyme A. Finally, catalysis by a transferase (*Criterion 5*) is almost always the case, the few exceptions being the coupling of hydrazines with carbonyl compounds (*Chapt. 4.8*) and some nonenzymatic conjugations with glutathione (*Chapt. 4.7*).




Fig. 4.5. This *Figure* and the next one illustrate the deep analogy between the physiological reactions of *endobiotic conjugation* and the conjugation of xenobiotics. Their graphical similarity with *Fig. 1.23* in *Part 1* [1] is not fortuitous. As shown here, a *waste product* of physiological metabolism (e.g., bilirubin, a toxic breakdown product of hemoglobin), an *endogenous compound* (e.g., the neurotransmitter noradrenaline), or a *nutrient* (e.g., a fatty acid) is captured by a transferase. The latter catalyzes the transfer of the adequate conjugating moiety from the cofactor to the substrate, yielding a *conjugate*. These reactions have evolved to fulfill a variety of functions, as classified in the *Figure*. Thus, the toxic *bilirubin* is detoxified by conjugation with glucuronic acid, the resulting glucuronide being excreted in the bile. The case of noradrenaline is different, being *N*-methylated to the neurotransmitter adrenaline or *O*-methylated to an inactive metabolite. The case of metabolic intermediates in *anabolism* (synthetic metabolism) and *catabolism* (breakdown metabolism) is illustrated with fatty acids, whose coenzyme A conjugates can undergo anabolism by C_2 chain elongation, or catabolism by β -oxidation.




Fig. 4.6. Reactions of xenobiotic conjugation have evolved from physiological conjugations to fulfill *protective functions* [10]. Thus, a xenobiotic containing an adequate target group, or a phase I metabolite, is captured and metabolized by a transferase. As we shall see, some transferases recognize endobiotics and xenobiotics alike (e.g., catechol *O*-methyltransferase), while others have diversified and are specialized to some extent toward endobiotics or xenobiotics (e.g., UDP-glucuronyl-transferases). As a rule, drug conjugation *inactivates* the substrate, but there are only few noteworthy exceptions such as the highly active morphine 6-*O*-glucuronide. Similarly, *toxicity* is usually greatly decreased by conjugation (e.g., *N*-methylpyridinium), but, as we shall see, there are numerous examples of conjugations leading to *toxification*. Some conjugates may indeed be reactive (e.g., some *acyl glucuronides*), whereas others are highly lipophilic and may accumulate in tissues as *residues* (e.g., some mixed triglycerides). Such exceptions should not hide the fact that the greatly increased hydrophilicity of many conjugates relative to their parent compound facilitates their excretion. What is more, a *co-evolution of transferases and transporters* is believed to have occurred, such that the formation of polar conjugates (e.g., glucuronides and glutathione derivatives) is coupled to their *active excretion* [11].